Tolvaptan: Dosing, Monitoring, Contraindications, and Adverse Effects
For ADPKD, initiate tolvaptan at 45 mg upon waking and 15 mg 8 hours later, titrating weekly to a target of 90 mg AM/30 mg PM based on tolerability, with mandatory monthly liver function monitoring for 18 months, then every 3 months thereafter. 1
Dosing for ADPKD
Initial Dosing
- Starting dose: 45 mg in the morning upon waking + 15 mg 8 hours later 1
- Begin on a non-working day to allow patients to observe and adapt to aquaretic effects 2
Titration Schedule
- Week 1+: Increase to 60 mg AM + 30 mg PM
- Week 2+: Increase to target dose of 90 mg AM + 30 mg PM
- Titrate at intervals ≥1 week based on patient tolerability 1
- Continue treatment until approaching kidney replacement therapy 1
Dose Adjustments
Hold or downtitrate tolvaptan for: 1
- Concurrent CYP3A inhibitors (strong: itraconazole, ketoconazole, clarithromycin, ritonavir; moderate: fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice)
- Intolerance or side effects
- Elevated liver enzymes
Skip doses when at risk of volume depletion: 1
- Limited water access
- Increased fluid losses (vomiting, diarrhea)
- Activities in warm weather
- Any "sick day" scenario
Treatment Duration
- Can continue in patients >55 years and/or eGFR <25 mL/min/1.73 m² if well tolerated 1
Dosing for Hyponatremia
This formulation (generic tolvaptan tablets) is contraindicated for ADPKD outside FDA-approved REMS due to hepatotoxicity risk. 3
For hyponatremia (hypervolemic/euvolemic):
- Starting dose: 15 mg once daily
- Titration: Increase to 30 mg, then maximum 60 mg once daily at intervals ≥24 hours
- Duration limit: Maximum 30 days to minimize liver injury risk 3
- Must initiate and re-initiate in hospital with close serum sodium monitoring 3
Monitoring Requirements
Liver Function Tests (ADPKD)
Mandatory monitoring schedule: 1, 2
- Monthly for first 18 months
- Every 3 months thereafter until discontinuation
- Obtain morning blood samples before tolvaptan dose
Management of Liver Enzyme Elevations
If AST/ALT ≥3× ULN or >2× baseline (even if <2× ULN): 1
- Hold tolvaptan immediately
- Repeat LFTs within 48-72 hours
- Assess for other etiologies
If AST/ALT >2× ULN with symptoms (fatigue, nausea, vomiting, anorexia, right upper quadrant pain, fever, rash, jaundice, pruritus, abdominal distention): 1
- Hold tolvaptan immediately
- Follow same algorithm as above
Permanent discontinuation required if: 1
- Transaminases remain ≥3× ULN on repeat testing
- No alternative explanation for liver injury identified
- Per U.S. label: Do not restart if AST/ALT >3× ULN with signs/symptoms of hepatic injury
Rechallenge considerations: 1
- May consider after LFTs normalize in patients with mild transaminase elevations
- Requires increased monitoring frequency
Other Monitoring
- Serum sodium: Provides insight into adequacy of water intake 1
- Serum potassium: Monitor in patients with K+ >5 mEq/L or on drugs that increase potassium 3
- eGFR: Expect small, reversible reduction (up to 10%) reflecting impact on compensatory hyperfiltration 1, 2
Contraindications
Absolute Contraindications 3
- ADPKD treatment outside FDA-approved REMS (for generic formulation)
- Unable to sense or respond to thirst
- Hypovolemic hyponatremia
- Concurrent strong CYP3A inhibitors
- Anuria
- Hypersensitivity to tolvaptan (anaphylactic shock, generalized rash)
Relative Contraindications/Cautions
- Underlying liver disease (avoid use) 3
- Severe malnutrition, alcoholism, advanced liver disease (risk of osmotic demyelination) 3
- Pregnancy (may cause fetal harm) 3
Adverse Effects
Most Common (Aquaretic Effects)
Occur in majority of patients due to mechanism of action: 1, 2
- Polyuria/pollakiuria: Averaging 5-7 L/day urine output
- Thirst: 7.7-40.3% of patients
- Dry mouth: 4.2-23.0% of patients
- Nocturia: Significant impact on sleep and quality of life
- Effects begin 1-2 hours post-dose, peak at 4-8 hours, resolve within 24 hours of withdrawal 2
Serious Adverse Effects
Idiosyncratic Drug-Induced Liver Injury (IDILI): 1, 4
- Incidence: ~5% develop transaminases >3× ULN (vs. 1% placebo)
- Timing: Most often during first 18 months
- Resolution: Within 1-4 months after cessation
- Severe cases: Rare acute liver failure requiring transplantation reported 2, 3
Osmotic Demyelination Syndrome (for hyponatremia indication): 3
- Risk with too-rapid sodium correction (>12 mEq/L/24 hours)
- Manifests as dysarthria, mutism, dysphagia, lethargy, spastic quadriparesis, seizures, coma, death
- Higher risk in severe malnutrition, alcoholism, advanced liver disease
Other Adverse Effects: 1
- Hyperuricemia and rarely gout
- Hyperkalemia (especially with RAAS inhibitors) 2
- Dehydration/hypovolemia requiring intervention
Real-World Discontinuation Rates
- 23-29% discontinuation over 1-8 years in observational studies 2
- Primary reasons: aquaretic intolerance (4.2%), hepatic adverse events (2.1%), lifestyle impact
Patient Counseling Essentials
Fluid Management 1, 2
- Drink liquids without sugar or fat to replace urinary losses
- Adopt low-sodium intake (reduces polyuria)
- Avoid fluid restriction during first 24 hours
- Drink 1-2 glasses before bedtime and with each nocturia episode
- Proactively drink water throughout day to prevent dehydration symptoms (headache, lethargy, fatigue, dizziness)
Lifestyle Adaptations 2
- Plan daily schedules around frequent urination
- Identify accessible restrooms at work/public spaces
- Most patients adapt within days to months
- Encourage optimistic mindset about tolerability
Sick-Day Plan 1
Skip doses during:
- Limited water access
- Increased fluid losses (vomiting, diarrhea)
- Warm weather activities
- Any volume depletion risk
Clinical Efficacy (ADPKD)
Evidence from TEMPO 3:4 and REPRISE trials: 1, 2
- Slows eGFR decline by 1.3 mL/min/1.73 m²/year
- Reduces total kidney volume growth by 2.7% annually
- Decreases UTI, kidney stones, hematuria, and kidney pain events
- Real-world data shows slowed TKV growth (6.58% to 3.71%/year) 2